Frontiers in pharmacology · 2026
Modulation of disease-associated gut microbiota by Schisandra chinensis: a literature review.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Zhimei, Wang Caiwen, Fan Hui, Yue Yifei, Sun Tianxia, Sun Liping
Аннотация
BACKGROUND: To clarify the mechanism by which Schisandra chinensis regulates the disease-related gut microbiota and to identify potential directions for future research.
METHODS: Relevant literature published between 2020 and 2025 was retrieved from Google scholar and NCBI PubMed. Two authors screened the literature based on titles and abstracts, followed by full-text screening by another two authors to ensure the inclusion of eligible studies.
RESULTS: We found in 61 studies that S. chinensis rich in polysaccharides and lignans, which are primary bioactive compounds involved in modulating gut microbiota composition. These compounds have been extensively studied for their ability to rebalance gut microbiota, repair the intestinal barrier function, increase short-chain fatty acids levels, and regulate metabolic pathways. Therefore, S. chinensis alleviates the symptoms caused by ulcerative colitis, antibiotic-associated diarrhea, alcohol-associated liver disease, type 2 diabetes mellitus, Alzheimer's disease, non-alcoholic fatty liver disease, systemic inflammation, and neurobehavioral alterations associated with mental illness. Additionally, another study suggested that lignans influence bile acid production by modulating gut microbiota.
CONCLUSION: Current research on S. chinensis regulate gut microbiota, which have demonstrated therapeutic effects in disease. However, the precis mechanisms of S. chinensis regulated the gut microbiota remain unclear, and high-quality clinical trials are lacking to validate the efficacy of S. chinensis in humans.
METHODS: Relevant literature published between 2020 and 2025 was retrieved from Google scholar and NCBI PubMed. Two authors screened the literature based on titles and abstracts, followed by full-text screening by another two authors to ensure the inclusion of eligible studies.
RESULTS: We found in 61 studies that S. chinensis rich in polysaccharides and lignans, which are primary bioactive compounds involved in modulating gut microbiota composition. These compounds have been extensively studied for their ability to rebalance gut microbiota, repair the intestinal barrier function, increase short-chain fatty acids levels, and regulate metabolic pathways. Therefore, S. chinensis alleviates the symptoms caused by ulcerative colitis, antibiotic-associated diarrhea, alcohol-associated liver disease, type 2 diabetes mellitus, Alzheimer's disease, non-alcoholic fatty liver disease, systemic inflammation, and neurobehavioral alterations associated with mental illness. Additionally, another study suggested that lignans influence bile acid production by modulating gut microbiota.
CONCLUSION: Current research on S. chinensis regulate gut microbiota, which have demonstrated therapeutic effects in disease. However, the precis mechanisms of S. chinensis regulated the gut microbiota remain unclear, and high-quality clinical trials are lacking to validate the efficacy of S. chinensis in humans.